Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC)
23 septembra, 2020 4:51 pmMeeting: 2018 ASCO Annual Meeting Track: Genitourinary (Nonprostate) Cancer Abstract number: 4504 Authors: Jonathan E. Rosenberg, Srikala...
First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt)
23 septembra, 2020 4:51 pmMeeting: 2018 ASCO Annual Meeting Track: Genitourinary (Nonprostate) Cancer Abstract number: 4503 Authors: Arlene O. Siefker-Radtke, Andrea...
Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC)
23 septembra, 2020 4:51 pmMeeting: 2018 ASCO Annual Meeting Track: Genitourinary (Nonprostate) Cancer Abstract number: 4511 Authors: Bernard Escudier, Robert J....
A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high-risk prostate cancer: Results of SPCG-13 trial
23 septembra, 2020 4:51 pmMeeting: 2018 ASCO Annual Meeting Track: Genitourinary (Prostate) Cancer Abstract number: 5000 Authors: Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, Marie...
Adjuvant Docetaxel Fails to Improve DFS for Intermediate- or High-Risk Prostate Cancer
23 septembra, 2020 4:51 pmJune 14, 2018 Treatment with docetaxel without prednisone failed to improve biochemical disease-free survival (DFS) compared with surveillance in...
SPRÁVA Z VÝROČNEJ KONFERENCIE AMERICKEJ ONKOLOGICKEJ SPOLOČNOSTI 2018
23 septembra, 2020 4:51 pmV dňoch 1. – 5. júna 2018 sa v americkom Chicagu uskutočnila výročná konferencia Americkej onkologickej spoločnosti (ASCO). Prezentované boli mnohé zaujímavé...
Adjuvant chemotherapy for pathological stage I non-small cell lung cancer with high-risk factors for recurrence: A multicenter study
18 septembra, 2020 8:01 pmAuthors: Yasuhiro Tsutani, Kentaro Imai, Hiroyuki Ito, et. al. Abstract: 8500 Citation: J Clin Oncol 37, 2019 (suppl;...
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3)
18 septembra, 2020 8:01 pmAuthors: David J. Kwiatkowski, Valerie W. Rusch, Jamie E. Chaft, et. al. Abstract: 8503 Clinical Trial Registry Number:...
Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) Anaplastic Lymphoma Kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK + non-small cell lung cancer (NSCLC)
18 septembra, 2020 8:01 pmAuthors: Tom Stinchcombe, Robert Charles Doebele, Xiaofei F. Wang, et. al. Abstract: 9027 Clinical Trial Registry Number: NCT02706626...
Brigatinib in pre-treated patients with ALK-positive advanced NSCLC
18 septembra, 2020 8:01 pmAuthors: Renaud Descourt, Maurice Perol, Gaelle Rousseau-Bussac, et. al. Abstract: 9045 Citation: J Clin Oncol 37, 2019 (suppl;...